Patents by Inventor Gerhard Frey

Gerhard Frey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12187801
    Abstract: The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: January 7, 2025
    Assignees: Exuma Biotech Corp., BioAtla. Inc.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, Jr., Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20240417886
    Abstract: Methods of generating conditionally active biologic proteins, in particular therapeutic or diagnostic proteins, which are more active at an aberrant condition than at a normal physiological condition. The methods include discovery methods using libraries of proteins and assays employing physiological concentrations of components of bodily fluids. The conditionally active biologic proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety. Criteria for selecting starting proteins for the discovery methods, as well as formats of the proteins are also disclosed.
    Type: Application
    Filed: August 30, 2024
    Publication date: December 19, 2024
    Applicant: BioAtla Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20240400659
    Abstract: A polypeptide or conditionally active protein suitable for prevention or treatment of a neurodegenerative disease that binds to ApoE. The conditionally active protein binds to ApoE with an increased binding activity at an aberrant condition such as an acidic pH in a dementia brain in comparison with the binding activity to ApoE at a normal physiological condition such as the pH of blood. A method for generating the conditionally active protein is also provided.
    Type: Application
    Filed: October 17, 2022
    Publication date: December 5, 2024
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Christina Wheeler, Jing Wang, Matthew Lucas, Haizhen Liu, Hwai Wen Chang, Gerhard Frey
  • Patent number: 12110611
    Abstract: Methods of generating conditionally active biologic proteins, in particular therapeutic or diagnostic proteins, which are more active at an aberrant condition than at a normal physiological condition. The methods include discovery methods using libraries of proteins and assays employing physiological concentrations of components of bodily fluids. The conditionally active biologic proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety. Criteria for selecting starting proteins for the discovery methods, as well as formats of the proteins are also disclosed.
    Type: Grant
    Filed: January 11, 2022
    Date of Patent: October 8, 2024
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 12097080
    Abstract: A labelling system includes a labelling plate being adapted to be removably connected with a sterile container, wherein the labelling plate includes interfaces for at least one label (e.g. barcode) and at least one identification tag (e.g. RFID). The interfaces can removably hold the at least one identification tag and/or the at least one label at the separate labelling plate.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: September 24, 2024
    Assignees: Aesculap Inc., Aesculap AG
    Inventors: Elmar Heid, Gerhard Frey, Frank Weller, Tommy Schubert, Edward Nuber
  • Publication number: 20240199746
    Abstract: An antibody or antibody fragment having a heavy chain variable region and/or light chain variable region that specifically binds to Ax1 protein. Immunoconjugates, pharmaceutical compositions and kits comprising the antibodies and antibody fragments are also provided. Also disclosed are methods of treating Ax1-expressing cancers using the antibodies, antibody fragments, immunoconjugates and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: January 2, 2024
    Publication date: June 20, 2024
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20240141035
    Abstract: An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.
    Type: Application
    Filed: October 23, 2023
    Publication date: May 2, 2024
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang, William Boyle
  • Publication number: 20240117067
    Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein. Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: November 14, 2023
    Publication date: April 11, 2024
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20240092901
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Ror2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Ror2 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: August 29, 2023
    Publication date: March 21, 2024
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11897959
    Abstract: An antibody or antibody fragment having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein. Immuoconjugages, pharmaceutical compositions and kits comprising the antibodies and antibody fragments are also provided. Also disclosed are methods of treating Axl-expressing cancers using the antibodies, antibody fragments, immunoconjugates and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: February 13, 2024
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11882976
    Abstract: A liquid distributor for a liquid-transfer system of a conveyor dishwasher has first, second and third connections. The liquid sprayed in at least one final-rinse zone of the conveyor dishwasher can be fed to the liquid distributor via the first connection, wherein some of the liquid fed to the liquid distributor can be discharged, via the second connection, to a line system which can be connected to the second connection, and wherein the rest of the liquid fed to the liquid distributor can be discharged, via the third connection, to at least one line system which can be connected to the third connection. The liquid distributor has an interchangeable aperture component, which defines the fraction of liquid which is fed to the liquid distributor via its first connection and is to be discharged, via the second connection, to the line system which can be connected to the second connection.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: January 30, 2024
    Assignee: ILLINOIS TOOL WORKS INC.
    Inventors: Frank Zoller, Matthias Lange, Gerhard Frei
  • Patent number: 11879011
    Abstract: A polypeptide having a heavy chain variable region and/or a light chain variable region that specifically binds to Ror2 protein, as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region, are provided. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: January 23, 2024
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11851499
    Abstract: Isolated polypeptides having a heavy chain variable region and/or light chain variable region that specifically binds to EpCAM protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to EpCAM protein Pharmaceutical compositions and kits comprising the polypeptide and antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: December 26, 2023
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Patent number: 11834472
    Abstract: An anti-IL-22 antibody or antibody fragment that binds to both human IL-22 and a mammalian IL-22 as well as modified anti-IL-22 antibodies and antibody fragments. Pharmaceutical compositions and kits comprising the antibody or antibody fragment are also provided. Also provided are methods for treatment of various IL-22 mediated conditions and diseases.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: December 5, 2023
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang, William Boyle
  • Publication number: 20230374702
    Abstract: A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.
    Type: Application
    Filed: June 27, 2023
    Publication date: November 23, 2023
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20230332135
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Application
    Filed: June 14, 2023
    Publication date: October 19, 2023
    Applicant: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11773509
    Abstract: A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: October 3, 2023
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11718844
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: August 8, 2023
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20230192858
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to CTLA4 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to CTLA4 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: November 17, 2022
    Publication date: June 22, 2023
    Applicant: BioAtla, Inc.
    Inventors: Jay M. Short, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20230072955
    Abstract: The present disclosure provides chimeric antigen receptors (CARs), and nucleic acids comprising nucleotide sequences encoding the CARs, that bind to HER2, and conditionally active biologic (CAB) CARs that bind to HER2. The present disclosure provides cells genetically modified to produce the CARs, delivery suspensions comprising these genetically modified cells, and methods for making such cells. The CARs of the present disclosure can be used in various methods, which are also provided, including methods for activating immune cells under certain conditions, and methods for performing adoptive cell therapy such as CAR therapy, for example CAR therapy against cancer.
    Type: Application
    Filed: January 23, 2021
    Publication date: March 9, 2023
    Applicants: Exuma Biotech Corp, BioAtla, Inc.
    Inventors: Gregory Ian Frost, James Joseph Onuffer, JR., Anirban Kundu, Jay M. Short, Gerhard Frey, Hwai Wen Chang